Thomas W. Beetham - 15 Feb 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (MGTA)

Role
Title: Chief Legal Officer and Secretary
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Thomas W. Beetham
Issuer symbol
MGTA
Transactions as of
15 Feb 2022
Transactions value $
$0
Form type
4
Filing time
17 Feb 2022, 16:15:40 UTC
Previous filing
20 Sep 2021
Next filing
19 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGTA Stock Option (Right to Buy) Award $0 +75K $0.00 75K 15 Feb 2022 Common Stock 75K $3.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022.

Remarks:

Title: Chief Legal Officer and Secretary